Design and Validation of a Novel Generic Platform for the Production of Tetravalent IgG1-like Bispecific Antibodies
Open Access
- 1 April 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 196 (7) , 3199-3211
Abstract
We have designed and validated a novel generic platform for production of tetravalent IgG1-like chimeric bispecific Abs. The VH-CH1-hinge domains of mAb2 are fused through a peptidic linker to the N terminus of mAb1 H chain, and paired mutations at the CH1-CL interface mAb1 are introduced that force the correct pairing of the two different free L chains. Two different sets of these CH1-CL interface mutations, called CR3 and MUT4, were designed and tested, and prototypic bispecific Abs directed against CD5 and HLA-DR were produced (CD5xDR). Two different hinge sequences between mAb1 and mAb2 were also tested in the CD5xDR-CR3 or -MUT4 background, leading to bispecific Ab (BsAbs) with a more rigid or flexible structure. All four Abs produced bound with good specificity and affinity to CD5 and HLA-DR present either on the same target or on different cells. Indeed, the BsAbs were able to efficiently redirect killing of HLA-DR+ leukemic cells by human CD5+ cytokine-induced killer T cells. Finally, all BsAbs had a functional Fc, as shown by their capacity to activate human complement and NK cells and to mediate phagocytosis. CD5xDR-CR3 was chosen as the best format because it had overall the highest functional activity and was very stable in vitro in both neutral buffer and in serum. In vivo, CD5xDR-CR3 was shown to have significant therapeutic activity in a xenograft model of human leukemia.Keywords
This publication has 60 references indexed in Scilit:
- Alternative molecular formats and therapeutic applications for bispecific antibodiesMolecular Immunology, 2015
- Tumor-Antigen–Binding Bispecific Antibodies for Cancer TreatmentSeminars in Oncology, 2014
- Antibody Therapeutics in CancerScience, 2013
- Maturing antibody–drug conjugate pipeline hits 30Nature Reviews Drug Discovery, 2013
- Dual targeting strategies with bispecific antibodiesmAbs, 2012
- Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free SurvivalJournal of Clinical Oncology, 2011
- Chemical generation of bispecific antibodiesProceedings of the National Academy of Sciences, 2010
- Extremely potent, rapid and costimulation‐independent cytotoxic T‐cell response against lymphoma cells catalyzed by a single‐chain bispecific antibodyInternational Journal of Cancer, 2002
- Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokineticsJournal of Molecular Biology, 1999
- Quadroma-Secreted Bi(Interferon Alpha 2—Peroxidase) Specific Antibody Suitable for One-Step ImmunoassayHybridoma, 1992